IRIS Accounts Production v24.1.0.576 08302452 Board of Directors 1.12.22 30.11.23 30.11.23 0 0 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh083024522022-11-30083024522023-11-30083024522022-12-012023-11-30083024522021-11-30083024522021-12-012022-11-30083024522022-11-3008302452ns15:EnglandWales2022-12-012023-11-3008302452ns14:PoundSterling2022-12-012023-11-3008302452ns10:Director12022-12-012023-11-3008302452ns10:PrivateLimitedCompanyLtd2022-12-012023-11-3008302452ns10:SmallEntities2022-12-012023-11-3008302452ns10:AuditExempt-NoAccountantsReport2022-12-012023-11-3008302452ns10:SmallCompaniesRegimeForDirectorsReport2022-12-012023-11-3008302452ns10:SmallCompaniesRegimeForAccounts2022-12-012023-11-3008302452ns10:FullAccounts2022-12-012023-11-3008302452ns10:OrdinaryShareClass12022-12-012023-11-3008302452ns10:Director22022-12-012023-11-3008302452ns10:Director32022-12-012023-11-3008302452ns10:Director42022-12-012023-11-3008302452ns10:RegisteredOffice2022-12-012023-11-3008302452ns5:CurrentFinancialInstruments2023-11-3008302452ns5:CurrentFinancialInstruments2022-11-3008302452ns5:Non-currentFinancialInstruments2023-11-3008302452ns5:Non-currentFinancialInstruments2022-11-3008302452ns5:ShareCapital2023-11-3008302452ns5:ShareCapital2022-11-3008302452ns5:RetainedEarningsAccumulatedLosses2023-11-3008302452ns5:RetainedEarningsAccumulatedLosses2022-11-3008302452ns5:FurnitureFittings2022-12-012023-11-3008302452ns5:FurnitureFittings2022-11-3008302452ns5:FurnitureFittings2023-11-3008302452ns5:FurnitureFittings2022-11-3008302452ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-11-3008302452ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-11-3008302452ns5:Non-currentFinancialInstrumentsns5:BetweenOneTwoYears2023-11-3008302452ns5:Non-currentFinancialInstrumentsns5:BetweenOneTwoYears2022-11-3008302452ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2023-11-3008302452ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2022-11-3008302452ns5:DeferredTaxation2022-11-3008302452ns5:DeferredTaxation2022-12-012023-11-3008302452ns5:DeferredTaxation2023-11-3008302452ns10:OrdinaryShareClass12023-11-3008302452ns5:RetainedEarningsAccumulatedLosses2022-11-3008302452ns5:RetainedEarningsAccumulatedLosses2022-12-012023-11-30
REGISTERED NUMBER: 08302452 (England and Wales)



















Unaudited Financial Statements

for the Year Ended 30 November 2023

for

PHARMACEUTICS (UK) LTD

PHARMACEUTICS (UK) LTD (REGISTERED NUMBER: 08302452)






Contents of the Financial Statements
for the Year Ended 30 November 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


PHARMACEUTICS (UK) LTD

Company Information
for the Year Ended 30 November 2023







DIRECTORS: Dr Qamar Nawaz
Dr Shahid Raza
Dr Syed Ehtisham Abidi
Mr Amar Nawaz





REGISTERED OFFICE: 9 Spur Road
Isleworth
Middlesex
TW7 5BD





REGISTERED NUMBER: 08302452 (England and Wales)





ACCOUNTANTS: Brindleys Limited
2 Wheeleys Road
Edgbaston
Birmingham
West Midlands
B15 2LD

PHARMACEUTICS (UK) LTD (REGISTERED NUMBER: 08302452)

Balance Sheet
30 November 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 3,017 3,550

CURRENT ASSETS
Debtors 5 378,459 331,738
Cash at bank and in hand 34,837 60,324
413,296 392,062
CREDITORS
Amounts falling due within one year 6 604,725 605,700
NET CURRENT LIABILITIES (191,429 ) (213,638 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(188,412

)

(210,088

)

CREDITORS
Amounts falling due after more than one year 7 15,513 25,512
NET LIABILITIES (203,925 ) (235,600 )

CAPITAL AND RESERVES
Called up share capital 10 200 200
Retained earnings 11 (204,125 ) (235,800 )
SHAREHOLDERS' FUNDS (203,925 ) (235,600 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 November 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 November 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

PHARMACEUTICS (UK) LTD (REGISTERED NUMBER: 08302452)

Balance Sheet - continued
30 November 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Comprehensive Income has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 2 April 2024 and were signed on its behalf by:





Dr Shahid Raza - Director


PHARMACEUTICS (UK) LTD (REGISTERED NUMBER: 08302452)

Notes to the Financial Statements
for the Year Ended 30 November 2023

1. STATUTORY INFORMATION

Pharmaceutics (UK) Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Fixtures and fittings - 15% on reducing balance

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2022 - NIL).

PHARMACEUTICS (UK) LTD (REGISTERED NUMBER: 08302452)

Notes to the Financial Statements - continued
for the Year Ended 30 November 2023

4. TANGIBLE FIXED ASSETS
Fixtures
and
fittings
£   
COST
At 1 December 2022
and 30 November 2023 10,659
DEPRECIATION
At 1 December 2022 7,109
Charge for year 533
At 30 November 2023 7,642
NET BOOK VALUE
At 30 November 2023 3,017
At 30 November 2022 3,550

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Other debtors 195,850 195,850
VAT 240 -
Deferred tax asset 182,369 135,888
378,459 331,738

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Bank loans and overdrafts (see note 8) 11,151 11,151
Other creditors 318,221 318,221
Directors' current accounts 274,753 274,753
Accrued expenses 600 1,575
604,725 605,700

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2023 2022
£    £   
Bank loans (see note 8) 15,513 25,512

PHARMACEUTICS (UK) LTD (REGISTERED NUMBER: 08302452)

Notes to the Financial Statements - continued
for the Year Ended 30 November 2023

8. LOANS

An analysis of the maturity of loans is given below:

2023 2022
£    £   
Amounts falling due within one year or on demand:
Bank loans 11,151 11,151

Amounts falling due between one and two years:
Bank loans - 1-2 years 11,151 11,151

Amounts falling due between two and five years:
Bank loans - 2-5 years 4,362 14,361

9. DEFERRED TAX
£   
Balance at 1 December 2022 (135,888 )
Provided during year (46,481 )
Balance at 30 November 2023 (182,369 )

10. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2023 2022
value: £    £   
200 Ordinary 1 200 200

11. RESERVES
Retained
earnings
£   

At 1 December 2022 (235,800 )
Profit for the year 31,675
At 30 November 2023 (204,125 )